Strongyloides Stercoralis in Bone Marrow Transplant Recipients in the UK
SSSSBMTUK
Seroprevalence and Impact of Screening for Strongyloides Stercoralis in Bone Marrow Transplant Recipients in the UK
1 other identifier
observational
480
0 countries
N/A
Brief Summary
Strongyloidiasis is a worm infection which affects more than 100 million people, mostly in Africa, Asia and Latin America, and can cause severe illness in people with reduced immunity. In the UK, the number of people with Strongyloides is not known. At Imperial College Healthcare NHS Trust (ICHNT) , screening for Stongyloides has recently been introduced as a standard-of-care for all patients undergoing BMT. In this study, investigators will perform two cross-sectional surveys and report the prevalence of Strongyloides in BMT recipients at ICHNT , as well as comparing clinical outcomes before/after the introduction of routine testing.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2021
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 5, 2021
CompletedFirst Posted
Study publicly available on registry
January 14, 2021
CompletedStudy Start
First participant enrolled
February 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2021
CompletedJanuary 14, 2021
January 1, 2021
10 months
January 5, 2021
January 13, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Strongyloides seropositivity
Baseline
Secondary Outcomes (10)
BMT outcome
Within first 12 months after BMT
BMT outcome
Within first 12 months after BMT
BMT outcome
Within first 12 months after BMT
BMT outcome
Within first 12 months after BMT
BMT outcome
Within first 12 months after BMT
- +5 more secondary outcomes
Study Arms (2)
Pre-screening group
Individuals undergoing bone marrow transplantation Jun 2018 - July 2020
Screened group
Individuals undergoing bone marrow transplantation July 2020 - July 2021
Interventions
Observational study only. Pre-screening group were not screened for Strongyloides, as per the standard of care at the time. Screened group were screened for Strongyloides, because the standard of care at our centre changed.
Eligibility Criteria
Individuals under the care of Haematology at ICHNT
You may qualify if:
- Adult patients
- Under care of Haematology at ICHNT
- Undergoing BMT Jun 2018 - July 2020 ('pre-screening group') or July 2020 - July 2021 ('screened group')
You may not qualify if:
- Age \< 18 years (i.e. managed as paediatric BMT)
- Previous BMT but no Strongyloides serology result available at the time of data collection
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 5, 2021
First Posted
January 14, 2021
Study Start
February 1, 2021
Primary Completion
December 1, 2021
Study Completion
December 1, 2021
Last Updated
January 14, 2021
Record last verified: 2021-01
Data Sharing
- IPD Sharing
- Will not share